Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization

Acta Pharmacologica Sinica

Volumn 32, Issue 5, 2011, Pages 664-672

  Chen, Dan Qi ^a   Wang, Xin ^a   Chen, Lin ^a   He, Jin Xue ^a   Miao, Ze Hong ^a   Shen, Jing Kang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

antitumor drug; cholic acid; cytarabine; liver

Indexed keywords

[5 [4 AMINO 2 OXOPYRIMIDIN 1(2H) YL] 3,4 DIHYDROXTETRAHYDROFURAN 2 YL]METHYL 3 [4 (3,7,12 TRIHYDROXY 10,13 DIMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHREN 17 YL PENTANAMIDO)PROPANOATE]; [5 [4 AMINO 2 OXOPYRIMIDIN 1(2H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYL 4 (3,7,12 TRIHYDROXY 10,13 DIMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHREN 17 YL)PENTANOATE; ANTINEOPLASTIC AGENT; CHOLIC ACID DERIVATIVE; CYTARABINE; CYTARABINE DERIVATIVE; N [1 [3,4 DIHYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIMIDIN 4 YL] 4 (3,7,12 TRIHYDROXY 10,13 DIMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHREN 17 YL)PENTANAMIDE; N [3 [1 [3,4 DIHYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIMIDIN 4 YLAMINO] 3 OXOPROPYL] 4 [3,7,12 TRIHYDROXY 10,13 DIMETHYLHEXDECAHYDRO 1H CYCLOPENTA[A]PHENANTHREN 17 YL)PHETANAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL ASSAY; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; LIQUID CHROMATOGRAPHY; LIVER HOMOGENATE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RAT; SIMULATION; STOMACH JUICE; TARGET ORGAN;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CHOLIC ACID; CHROMATOGRAPHY, LIQUID; CYTARABINE; DRUG DELIVERY SYSTEMS; HALF-LIFE; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIVER; MALE; MASS SPECTROMETRY; MICE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 79959758618     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.7     Document Type: Article

References (22)

1. Pallavicini MG. Cytosine arabinoside: Molecular, pharmacokinetic and cytokinetic considerations. Pharmacol Ther 1984; 25: 207-38. (Pubitemid 14015739)
2. Rustum M, Raymakers RA. 1-β-Arabinofuranosylcytosine in therapy of leukemia: Preclinical and clinical overview. Pharmacol Ther 1993; 56: 307-21.
3. Beumer JH, Eiseman JL, Parise RA, Florian Jr JA, Joseph E, D'Argenio DZ, et al. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6- tetrahydrouridine, a cytidine deaminase inhibitor in mice. Cancer Chemother Pharmacol 2008; 62: 457-64.
4. Hsi D, Ho W. Distribution of kinase and deaminase of 1-β-D- Arabinofuranosylcytosine in tissue of man and mouse. Cancer Res 1973; 33: 2816-20.
5. Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet 2002; 41: 705-18. (Pubitemid 34948193)
6. Novotny L, Rauko P. Cytarabine conjugates with biologically active molecules and their potential anticancer activity. Neoplasma 2009; 56: 177-86.
7. Miller LP, Pyesmany AF, Wolff LJ, Rogers PCJ, Siegel SE, Wells RJ, et al. Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children - A report from the childrens cancer study-group. Cancer 1991; 67: 2235-40.
8. Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, et al. Pharmacokinetics of N4-Behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res 1983; 43: 3412-6.
9. Rosti G, Bonifazi F, Trabacchi E, Vivo A, BAssi S, Martinelli G, et al. A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. Leukemia 2003; 17: 554-9. (Pubitemid 36395649)
10. Cheon EP, Hong JH, Han HK. Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells. J Pharm Pharmacol 2006; 58: 927-32. (Pubitemid 43967109)
11. Kery V, Novotny L, Tihlarik K, Haplová J, Kacuráková M, Sandula J, et al. Preparation, properties and antileukemic activity of arabinosylcytosine polysaccharide conjugates. Int J Biochem 1990; 22: 1203-7. (Pubitemid 20353317)
12. Hong CI, Nechaev A, West CR. Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl) cytosine conjugates of prednisolone and prednisone. J Med Chem 1979; 22: 1428-32.
13. Sievanen E. Exploitation of bile acid transport systems in prodrug design. Molecules 2007; 12: 1859-89.
14. Enhsen A, Kramer W, Wess G. Bile acids in drug discovery. Drug Discov Today 1998; 3: 409-18. (Pubitemid 28391982)
15. Tolle-Sander S, Lentz KA, Maeda DY, Coop A, Polli JE. Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm 2004; 1: 40-8.
16. Geldern TW, Tu N, Kym PR, Link JT, Jae H, Lai C, et al. Liver-selective glucocorticoid antagonists: A novel treatment for type 2 diabetes. J Med Chem 2004; 47: 4213-30. (Pubitemid 39056076)
17. Gabano E, Ravera M, Osella D. The drug targeting and delivery approach applied to Pt-Antitumour complexes. A coordination point of view. Curr Med Chem 2009; 16: 4544-80.
18. Jurcek O, Wimmer Z, Svobodova H, Bennettova B, Kolehmainen E, Drasar P. Preparation and preliminary biological screening of cholic acid-juvenoid conjugates. Steroids 2009; 74: 779-85.
19. Rohacova J, Marin ML, Martinez-Romero A, Diaz L, O'Connor JE, Gomez-Lechon MJ, et al. Fluorescent benzofurazan-cholic acid conjugates for in vitro assessment of bile acid uptake and its modulation by drugs. ChemMedChem 2009; 4: 466-72.
20. Hu P, Hou S, Jin H, Zhang J, Wang L. Synthesis and stability of bile acid conjugate lamivudine as a liver target prodrug. Central South Pharmacy 2005; 3: 13-5.
21. Ju J, Gitcho MA, Casmaer CA, Patil PB, Han D, Spencer SA, et al. Potentiation of insulin-stimulated glucose transport by the AMP-activated protein kinase. Am J Physiol Cell Physiol 2007; 292: 564-72.
22. Qing C, Miao ZH, Tong LJ, Zhang JS, Ding J. Actinomycin D inhibiting K562 cell apoptosis elicited by salvicine but not decreasing its cytotoxicity. Acta Pharmacol Sin 2003; 24: 415-21.